NCT04946305View on ClinicalTrials.gov

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

CompletedOBSERVATIONAL
Enrollment

89

Participants

Timeline

Start Date

May 10, 2022

Primary Completion Date

July 8, 2024

Study Completion Date

July 8, 2024

Conditions
Somatostatin Receptor-positive GEP-NET
Interventions
OTHER

Lutathera

Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (6)

13620

Novartis Investigative Site, Seongnam-si

03722

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

110-799

Novartis Investigative Site, Seoul

137-040

Novartis Investigative Site, Seoul

138-736

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY